Management of Uterine Müllerian Adenosarcoma with Extrauterine Metastatic Deposits

Guidozzi, F; Smith, Trudy; Koller, A.; Reinecke, L

doi:10.1006/gyno.2000.5757

Cited by 15 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the patients also received a pelvic lymphadenectomy and out of contact, while the other remains alive after 54 months of follow up. For stage III patients, it has been reported by Goidozzi et al 7 that they can survive without tumour recurrence for 34 to 56 months following a modified radical hysterectomy, bilateral adnexectomy and omentectomy with adjuvant chemotherapy pre-or postoperatively. In our study, one stage III patient who had deep muscular invasion and metastasis to pelvic lymph nodes died six months postoperatively.…”

Section: Treatment and Prognosismentioning

confidence: 96%

The diagnosis and treatment of Mullerian adenosarcoma of the uterus

Shi¹,

Liu²,

Peng³

et al. 2008

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

Section: Treatment and Prognosismentioning

confidence: 96%

The diagnosis and treatment of Mullerian adenosarcoma of the uterus

Shi¹,

Liu²,

Peng³

et al. 2008

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

“…Guidozzi described the history of three patients with stage II–III uterine AS, who received neoadjuvant chemotherapy and surgery in two cases and surgery followed by chemotherapy and radiotherapy in the third case, obtaining a long disease-free interval, ranging from 34 months to 56 months of follow-up ( 27 ).…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors in uterine adenosarcoma: subanalysis of the SARCUT study

Mancari,

Yusuf,

Macuks

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThe purpose of the study was to analyse the role of prognostic factors on the risk of recurrence and overall survival of patients with uterine adenosarcoma.MethodsA retrospective international multicentre study involving 46 centres collected 32 cases of uterine adenosarcoma, and these cases were included in the present subanalysis. Clinical and demographic features and tumour characteristics were gathered, as well as information on treatment and relapse. Disease-free and overall survival were analysed.ResultsThe 5-year disease-free survival (DFS) was 85.3% and the 5-year overall survival (OS) rate was 89.5%. The risk factors significantly associated with overall survival were age (HR 1.09, 95% CI 1.03–1.15; p = 0.004) and FIGO stage II–III (HR 17.75, 95% CI 2.87–109.93; p = 0.002). Patients who experienced early relapse (within 12 months) had a tumour size >30 mm and advanced stage. The majority of recurred cases were treated with radiotherapy or surgery and obtained a good response rate.ConclusionThe most significant prognostic factors in uterine adenosarcoma were age and FIGO stage and, indirectly, tumour size at diagnosis. The use of secondary surgery and/or radiotherapy could help in prolonging the disease-free status of the patients.

show abstract

“…The decision of giving post-surgery chemotherapy may be based on the extent of muscular invasion and sarcomatous growth. While optimum treatment has yet to be defined for stage-II patients, Guidozzi et al[19](2000) demonstrated that 34- to 56-month disease-free survival can be achieved in stage-III patients treated by neoadjuvant radiation therapy followed by radical surgery and then again by adjuvant radiation therapy followed by three chemotherapy cycles with carboplatinum and farmarubicin. Huang et al [12] (2009) proposed treatment with ifosfamide and cisplatinum in the extragenital forms with high sarcomatous growth.…”

Section: Discussionmentioning

confidence: 99%

Extragenital Müllerian adenosarcoma with pouch of Douglas location

et al. 2011

View full text Add to dashboard Cite

BackgroundOf all female genital tract tumors, 1-3% are stromal malignancies. In 8-10% of cases, these are represented by Müllerian adenosarcoma an extremely rare tumor characterized by a stromal component of usually low-grade malignancy and by a benign glandular epithelial component. Variant that arises in the pouch of Douglas is scarcely mentioned in the medical literature.Case PresentationA 49-year-old para-0 woman, was seen at our OB/GYN-UNIT because she complained vaguely of pelvic pain. She had a mass of undefined nature in the pouch of Douglas. A simple excision of the mass showed low-grade Müllerian adenosarcoma with areas of stromal overgrowth. One and a half year after surgery, at another hospital, a mass was detected in the patient's posterior vaginal fornix and removed surgically. Six months later she came back to our observation with vaginal bleeding and mass in the vaginal fornix. We performed radical surgery. The pathological examination showed recurrent adenosarcoma. Surgical treatment was supplemented by radiation therapy.ConclusionsThe case of Müllerian adenosarcoma reported here is the third known so far in the literature that was located in the pouch of Douglas. To date, only two other such cases have been reported, including one resulting from neoplastic degeneration of an endometriotic cyst.

show abstract

Management of Uterine Müllerian Adenosarcoma with Extrauterine Metastatic Deposits

Cited by 15 publications

References 8 publications

The diagnosis and treatment of Mullerian adenosarcoma of the uterus

The diagnosis and treatment of Mullerian adenosarcoma of the uterus

Prognostic factors in uterine adenosarcoma: subanalysis of the SARCUT study

Extragenital Müllerian adenosarcoma with pouch of Douglas location

Contact Info

Product

Resources

About